Combining ASBT inhibitor and FGF15 treatments enhances therapeutic efficacy against cholangiopathy in female but not male Cyp2c70 KO mice

[1]  P. Dawson,et al.  Ileal bile acid transporter inhibition in Cyp2c70 KO mice ameliorates cholestatic liver injury , 2022, Journal of lipid research.

[2]  Richard J. Thompson,et al.  Maralixibat for the treatment of PFIC: Long‐term, IBAT inhibition in an open‐label, Phase 2 study , 2022, Hepatology communications.

[3]  Rumei Li,et al.  Short-term obeticholic acid treatment does not impact cholangiopathy in Cyp2c70-deficient mice with a human-like bile acid composition. , 2022, Biochimica et biophysica acta. Molecular and cell biology of lipids.

[4]  N. LaRusso,et al.  Cellular senescence in the cholangiopathies , 2021, Current opinion in gastroenterology.

[5]  D. Lou,et al.  An Overview of 7α- and 7β-Hydroxysteroid Dehydrogenases: Structure, Specificity and Practical Application. , 2021, Protein and peptide letters.

[6]  Huaiwen Wang,et al.  Combined ASBT Inhibitor and FGF15 Treatment Improves Therapeutic Efficacy in Experimental Nonalcoholic Steatohepatitis , 2021, Cellular and molecular gastroenterology and hepatology.

[7]  J. Ridlon,et al.  Microbial Hydroxysteroid Dehydrogenases: From Alpha to Omega , 2021, Microorganisms.

[8]  A. Sanyal,et al.  Potent suppression of hydrophobic bile acids by aldafermin, an FGF19 analogue, across metabolic and cholestatic liver diseases , 2021, JHEP reports : innovation in hepatology.

[9]  J. C. Wolters,et al.  Cholangiopathy and Biliary Fibrosis in Cyp2c70-Deficient Mice Are Fully Reversed by Ursodeoxycholic Acid , 2020, Cellular and molecular gastroenterology and hepatology.

[10]  T. Hassanein,et al.  Volixibat in adults with non-alcoholic steatohepatitis: 24-week interim analysis from a randomized, phase II study. , 2020, Journal of hepatology.

[11]  F. Hildebrand,et al.  Intestinal Microbiome‐Macrophage Crosstalk Contributes to Cholestatic Liver Disease by Promoting Intestinal Permeability in Mice , 2020, Hepatology.

[12]  Satoru Takahashi,et al.  Regulation of bile acid metabolism in mouse models with hydrophobic bile acid composition[S] , 2019, Journal of Lipid Research.

[13]  J. C. Wolters,et al.  A human-like bile acid pool induced by deletion of hepatic Cyp2c70 modulates effects of FXR activation in mice[S] , 2019, Journal of Lipid Research.

[14]  M. Kummen,et al.  The gut microbial influence on cholestatic liver disease , 2019, Liver international : official journal of the International Association for the Study of the Liver.

[15]  P. Dawson,et al.  Animal models to study bile acid metabolism. , 2019, Biochimica et biophysica acta. Molecular basis of disease.

[16]  Bochu Wang,et al.  Structural and functional characterization of a novel acidophilic 7α‐hydroxysteroid dehydrogenase , 2019, Protein science : a publication of the Protein Society.

[17]  Bo Li,et al.  Comprehensive Analysis of Serum and Fecal Bile Acid Profiles and Interaction with Gut Microbiota in Primary Biliary Cholangitis , 2019, Clinical Reviews in Allergy & Immunology.

[18]  M. Karsdal,et al.  Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial. , 2019, Journal of hepatology.

[19]  Yi-horng Lee,et al.  Fibroblast Growth Factor 15–Dependent and Bile Acid–Independent Promotion of Liver Regeneration in Mice , 2018, Hepatology.

[20]  J. Walters,et al.  Guts and Gall: Bile Acids in Regulation of Intestinal Epithelial Function in Health and Disease. , 2018, Physiological reviews.

[21]  B. Leggett,et al.  NGM282 for Treatment of Patients With Primary Biliary Cholangitis: A Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Trial , 2018, Hepatology communications.

[22]  R. Giugliano,et al.  Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes Vytorin Efficacy International Trial) , 2018, Circulation.

[23]  R. Chapman,et al.  A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis , 2018, Hepatology.

[24]  R. Giugliano,et al.  Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With vs. Without Diabetes: Results from IMPROVE-IT , 2017 .

[25]  R. M. Learned,et al.  Engineered FGF19 eliminates bile acid toxicity and lipotoxicity leading to resolution of steatohepatitis and fibrosis in mice , 2017, Hepatology communications.

[26]  Y. Chong,et al.  Circulating FGF19 closely correlates with bile acid synthesis and cholestasis in patients with primary biliary cirrhosis , 2017, PloS one.

[27]  C. Brocker,et al.  Cyp2c70 is responsible for the species difference in bile acid metabolism between mice and humans[S] , 2016, Journal of Lipid Research.

[28]  M. Mokry,et al.  Gene expression profiling in human precision cut liver slices in response to the FXR agonist obeticholic acid. , 2016, Journal of hepatology.

[29]  Bochu Wang,et al.  The three-dimensional structure of Clostridium absonum 7α-hydroxysteroid dehydrogenase: new insights into the conserved arginines for NADP(H) recognition , 2016, Scientific Reports.

[30]  A. Baghdasaryan,et al.  Inhibition of intestinal bile acid absorption improves cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis. , 2016, Journal of hepatology.

[31]  A. Jegga,et al.  Pharmacological inhibition of apical sodium‐dependent bile acid transporter changes bile composition and blocks progression of sclerosing cholangitis in multidrug resistance 2 knockout mice , 2016, Hepatology.

[32]  R. M. Learned,et al.  Engineered fibroblast growth factor 19 reduces liver injury and resolves sclerosing cholangitis in Mdr2‐deficient mice , 2015, Hepatology.

[33]  R. Haque,et al.  Regulators of Gut Motility Revealed by a Gnotobiotic Model of Diet-Microbiome Interactions Related to Travel , 2015, Cell.

[34]  M. Trauner,et al.  New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond. , 2015, Journal of hepatology.

[35]  J. Chiang,et al.  Bile Acid Signaling in Metabolic Disease and Drug Therapy , 2014, Pharmacological Reviews.

[36]  G. Radda,et al.  Gastrointestinal transit measurements in mice with 99mTc-DTPA-labeled activated charcoal using NanoSPECT-CT , 2013, EJNMMI Research.

[37]  F. Bäckhed,et al.  Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. , 2013, Cell metabolism.

[38]  A. Odermatt,et al.  Hepatic reduction of the secondary bile acid 7-oxolithocholic acid is mediated by 11β-hydroxysteroid dehydrogenase 1. , 2011, The Biochemical journal.

[39]  C. Klaassen,et al.  Effects of feeding bile acids and a bile acid sequestrant on hepatic bile acid composition in mice[S] , 2010, Journal of Lipid Research.

[40]  G. Jahreis,et al.  Faecal steroid excretion in humans is affected by calcium supplementation and shows gender-specific differences , 2009, European journal of nutrition.

[41]  S. Strom,et al.  Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7α‐hydroxylase gene expression , 2009, Hepatology.

[42]  C. Klaassen,et al.  Tissue distribution and ontogeny of sulfotransferase enzymes in mice. , 2006, Toxicological sciences : an official journal of the Society of Toxicology.

[43]  P. Dawson,et al.  OSTα‐OSTβ: A major basolateral bile acid and steroid transporter in human intestinal, renal, and biliary epithelia , 2005 .

[44]  S. Kliewer,et al.  Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. , 2005, Cell metabolism.

[45]  P. Gérard,et al.  Epimerization of chenodeoxycholic acid to ursodeoxycholic acid by Clostridium baratii isolated from human feces. , 2004, FEMS microbiology letters.

[46]  R. van Haperen,et al.  Increased Fecal Bile Acid Excretion in Transgenic Mice With Elevated Expression of Human Phospholipid Transfer Protein , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[47]  C. Falany,et al.  Effects of dexamethasone on aryl (SULT1A1)- and hydroxysteroid (SULT2A1)-sulfotransferase gene expression in primary cultured human hepatocytes. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[48]  L. Moore,et al.  A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. , 2000, Molecular cell.

[49]  L. Hudson,et al.  Characterization and regulation of the NADP-linked 7 alpha-hydroxysteroid dehydrogenase gene from Clostridium sordellii , 1994, Journal of bacteriology.

[50]  G. Everson,et al.  Regulation of cholesterol and bile acid homoeostasis in bile-obstructed rats. , 1991, The Biochemical journal.

[51]  S. F. Baron,et al.  Cloning, sequencing, and expression of the gene coding for bile acid 7 alpha-hydroxysteroid dehydrogenase from Eubacterium sp. strain VPI 12708 , 1991, Journal of bacteriology.

[52]  T. Yoshimoto,et al.  Cloning and sequencing of the 7 alpha-hydroxysteroid dehydrogenase gene from Escherichia coli HB101 and characterization of the expressed enzyme , 1991, Journal of bacteriology.

[53]  D. Heuman.  Quantitative estimation of the hydrophilic-hydrophobic balance of mixed bile salt solutions. , 1989, Journal of lipid research.

[54]  K. Kobashi,et al.  Purification and characterization of 7 beta-hydroxysteroid dehydrogenase from Ruminococcus sp. of human intestine. , 1987, Journal of biochemistry.

[55]  J. Sutherland,et al.  Bile acid induction of 7 alpha- and 7 beta-hydroxysteroid dehydrogenases in Clostridium limosum. , 1985, Journal of lipid research.

[56]  K. Uchida,et al.  Changes in biliary and fecal bile acids in mice after treatments with diosgenin and beta-sitosterol. , 1984, Journal of lipid research.

[57]  B. White,et al.  Separation of 7 alpha- and 7 beta-hydroxysteroid dehydrogenase activities from clostridium absonum ATCC# 27555 and cellular response of this organism to bile acid inducers. , 1983, Journal of lipid research.

[58]  G. Tint,et al.  Transformation of chenodeoxycholic acid and ursodeoxycholic acid by human intestinal bacteria. , 1979, Gastroenterology.

[59]  H. Jaeschke,et al.  Sortilin 1 Loss-of-Function Protects Against Cholestatic Liver Injury by Attenuating Hepatic Bile Acid Accumulation in Bile Duct Ligated Mice , 2018, Toxicological sciences : an official journal of the Society of Toxicology.

[60]  C. Brocker,et al.  Cyp 2 c 70 is responsible for the species difference in bile acid metabolism between mice and humans , 2016 .

[61]  P. Dawson,et al.  OSTalpha-OSTbeta: a major basolateral bile acid and steroid transporter in human intestinal, renal, and biliary epithelia. , 2005, Hepatology.